General
Preferred name
TRIPTORELIN
Synonyms
AY 25650 ()
BIM 21003 ()
CL 118,532 ()
CL 118532 ()
Wy 42422 ()
Wy 42462 ()
Triptorelin acetate ()
[DTrp6]-LH-RH ()
Decapeptyl ()
triptorelin / gonadoreline-6-D-tryptophan acetate ()
TRIPTORELIN PAMOATE ()
Decapeptyl sr ()
CL-118532 ()
Tryptorelin ()
WY-42462 ()
AY-25650 ()
Gonapeptyl depot ()
Triptodur ()
Arvekap ()
Triptorelin embonate ()
Triptorelin (as embonate) ()
Trelstar ()
Salvacyl ()
Triptodur kit ()
Triptorelin (trifluoroacetate salt) ()
P&D ID
PD009214
CAS
140194-24-7
57773-63-4
2240176-35-4
Tags
available
drug
Approved by
FDA
First approval
2000
Drug Status
approved
vet_approved
Drug indication
Antineoplastic
Prostate cancer
Solid tumour/cancer
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
As is the case with many peptide molecules, there is some ambiguity as to the stereochemistry of triptorelin, therefore the chemical structure shown here may vary slightly from that displayed on the resources linked to from the table above. The marketed formulations contain triptorelin pamoate (PubChem CID 25074469) or triptorelin acetate (PubChem CID 25080282).
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
16
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
Natural product-based probes and drugs
ReFrame library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
54
Molecular Weight
1310.63
Hydrogen Bond Acceptors
15
Hydrogen Bond Donors
18
Rotatable Bonds
33
Ring Count
8
Aromatic Ring Count
6
cLogP
-2.09
TPSA
487.92
Fraction CSP3
0.42
Chiral centers
9.0
Largest ring
6.0
QED
0.01
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Target
GNRHR
GNRH Receptor
Indication
prostate cancer, breast cancer, precocious puberty, endometriosis, myoma, gender dysphoria
Disease Area
oncology, endocrinology, obstetrics/gynecology
MOA
gonadotropin releasing factor hormone receptor agonist
Biosynthetic Origin
Peptide (NRPS)
Therapeutic Indication
Hormone
Therapeutic Class
Hormone Therapy
Source data
